Information Provided By: 
Fly News Breaks for April 7, 2015
ASPX, TEVA
Apr 7, 2015 | 15:24 EDT
BMO Capital raised its EPS estimates for Teva (TEVA) and increased its price target on the stock to $75 from $64 on account of the expected launch of a treatment for chorea associated with Huntington’s disease in 3Q16 and a launch of a tardive dyskinesia drug in 3Q17 following the company's deal to buy Auspex (ASPX). The firm maintains its Outperform rating on Teva shares.
News For TEVA;ASPX From the Last 2 Days
There are no results for your query TEVA;ASPX
